Alar Pharmaceuticals

6785.TWO

5.33 USD

-0.14

-2.56%

Overview

Last close

5.33 usd

Market cap

355.78M usd

52 week high

9.84 usd

52 week low

3.40 usd

Target price

9.22 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

4076.4258

Price/Book Value

4.6697

Enterprise Value

283.84M usd

EV/Revenue

3243.5819

EV/EBITDA

413.1064

Key financials

Revenue TTM

87507.95 usd

Gross Profit TTM

68022.89 usd

EBITDA TTM

-5.26M usd

Earnings per Share

-0.04 usd

Dividend

N/A usd

Total assets

79.25M usd

Net debt

N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.